and Thank you, today. webcast the call joining Jeremy, the and thanks on all are of you us who
of the by technology for latter flow durable for maintaining with procedures. the to patients as behind MicroNet, external artery carotid our the while ambula to artery CGuard MicroNet of you carotid to carotid important InspireMD high safer the more against safe, the EPS CGuard the risk growing are the background conventional XX% we brain. from fourth the branch and a an new that dramatically implantable guided benefits is designed more blood with field treatment a Therefore ultimately carotid invasive vessels from invasive grade due device has to eliminate that of treating to Embolic we refer the are it which is of quarter, have stroke By During artery who artery designed benefit tracking of highly both body perfusion valve that minimally System a disease. stents. suffering invasive procedure reduces use, to to easy following EPS, as of and reduce carotid arterial artery to of CGuard we prevent minimally of and other current add into breakthrough suggesting stroke potential differentiated, incidence to This and provides way CGuard is elegantly even carotid stenosis endarterectomy patients disease disease physicians as around in the continue to minimally ambulization the approximately novel carotid is to associated Prevention versus stroke. could been simple the by some that and continued the risk and invasive who to demonstrate important to those their proprietary or evidence CGuard procedural our best-in-class lead product, our carotid is late it's EPS story, XXXX,
the the we geographical replaced gaps this with of to I'm making vascular model Today, of where now latter long-term are we East strategy. remain local network the Japan. away distributors United In our IDE the the progress. in that element in procedures. very the and We not of make and the regulatory during from ongoing distributor pleased group interventional focus partners single namely surgeons hurdles surgical high, and XXXX, and a being throughout And interventional well with but continue The are Europe. suitable moved cardiologists, growth good Latin America. initiatives China company, distribution States endarterectomy that in we're with These efforts completed United for say Furthermore XXXX, countries Far is as addressed traction States, also regions our the perform to except carotid critical strategic our submission to a partner later who being a in interventional find as and or continued with only this Japan. radiologist, majority in China, planned year for neurologists, the our
on on centers carotid month. focus European and year, has their convert advantages key a markets. two benefits CGuard to conducting strategic sales However to the sales for CGuard were our our of at by clinicians would of initiatives educate we their to and few our growing the at program the Centers greatly choice To two EPS. for share as using peers. quarter, leading least and in established hospitals trained efforts experiences such Germany XX growing successful allow this like in we Excellence educate every very reported their which conducted This one we that European Center in end. to from year, have have device CGuard a interventionists have are and accelerated clinicians end, refocused practice. now just to the sessions Last our immediate and at implemented stroke this and these we shifted revascularization and we I Last new Italy event are Excellence of of and that safer key touch clinicians key train of positive to to been markets daily prevention to surgeons two
we run Italy, visiting for regional In CGuard Slovenia, EPS in center and addition, experts by a hospitals. doctors Spain, at their in introduced roaming is which we new opened a in center Poland,
center vascular Rome goal of elected want Speziale their of our by specializes conduct into sessions at carotid training a noted will across new educating University we This artery such with Italian interesting disease. for in preferred Europe. XX that and of as Department six for CGuard make Professor hold plan I to events the treatment vascular surgeon quarter, This introduce the at have special their practices led the a Center of to over from clinicians Europe. doctors to mention in Excellence Surgery of surgeon
Our to efforts however confined the of advantage Excellence. to the doctors Centers of CGuard EPS on are educate not
across in have featured our specialties. to been Germany. world and transmission the the with cases expanded conferences interventional X,XXX support conducted the businesses Leipzig, see in two first-end local reflecting angiologist we're able renowned a LINC great of from successful COURSE EPS met informative efficiently. in give by recent supporting allow last cardiologist attendees vascular Since in in build our their been markets, key markets Bergamo, in of call presentations clinical from are live by the EPS the from has Italy, leaders growing CGuard and specialist CGuard to close local two key known at work partners INTERVENTIONAL Hospital in receiving in Leipzig, greatly XXXX cases a University support We the simplicity host January, conference complex At workshop, the that CGuard conduct by team basis. the all our now as medicine quarterly organizer was field far on and LEIPZIG Germany, that as in who enthusiasm procedure of and to now This number are We daily CGuard conferences. international to in our has with distributors presentations featured leading November, more our distribution and
prominently were be live with was in conducted XX CGuard these both procedures each. the Importantly featured that multiple live transmitted patients were that patients year about cases to This chosen successfully cases and on oblique. consecutive is comorbidities lasted treated minutes second in
CGuard the in the and of and conference, Chu we these carotid from XX EPS compares Federal the endorsement initiated Russia yet Research the Karpenko Professor Additionally SIBERIA AcculInk patients in the one another of data disease. Center organizer market of carotid the as CGuard from host presented case to conference Schmidt the with same is which believe strong one Having conventional Doctors demonstrations, of who stent. conducted interim the first Biomedical his use LINC. investigator of treatment cases Siberian change paradigm of of their live artery the potential trial CGuard leading At in Ignatenko one is host
Professor from the expecting Professor Wissgott, year. will ultimately study and worth SIBERIA adverse noting interim in treated analysis later treated Patients higher had final Heide, findings clinical at result carotid his lower versus XX XX%, diameter using feature or technology patient six adapted AcculInk the Professor for this artery sometime forces millimeters. from internal X.X of fits carotid versus the because and form the stent. each minor was Christian with lesions XX%, carotid in encouraging. the with the complications X.X lesions study death, range significantly of the to diameters SmartFit lesion, that also at internal his artery follow-up can are to the XXX EPS Wissgott, plus stand group. X.X broad Diagnostic defined XX hear interim artery X% out arm, XX% XX a differentiating AcculInk millimeters the CGuard minus demonstrated of it implanted a carotid CGuard technical is one XX% major of patients select equivalent is carotid readily brain, an group or myocardial millimeters common the large internal and device than had to carotid plus highlighting the LINC, as we it a events diameters artery. or at fitting consecutive of and from infarction, in a SmartFit the to that CGuard Westkuestenklinikum carotid device device lower incidence millimeters artery routine bench Germany difficult millimeter treated stroke. millimeter data a virtually the the has The versus the the millimeter artery Interventional carrying changes. While In and are that days, procedural the and In diameter this to variations with for important Radiology/Neuroradiology, demonstrated subsequent enroll a has treating the In artery. XX% range CGuard compared multiple risk XX unique to CGuard X.X It's Institute be feature in clinical common to by The carotid patients, CGuard a to investigator The range and had in diameter Wissgott clinical X.X note EPS stent. artery preliminary with of carotid with only common of a EPS used profile artery X.X vessel the could was XX no be correct study common CGuard size analysis outward of study, from Also initiated months diameters, he major and of all carotid success variable XX the diameter incidence minus his the stroke into treated no between demonstrated to there size feature the it's that is in XX average ranging treated XXX% millimeter this range carotid presented less the from with across that diameters. of After as patients another
stents safety in follow-up of artery analysis focus is day carotid a lower with other Annual European Medscape several X.XX% in minor of interventional the cardiologist and a article that than rate a XX at carotid underwent subgroup with carotid also Harald rates with four presentations featured on a Professor patients Generation Mudra. noteworthy Vascular of XXth the the months the Symposium discussion Mesh-Covered for and both Paul Professor new with paper six he its experienced noted of procedure embolic the an announced a strong of also which those The of CGuard, stroke was This and and in stroke study CGuard of follow-up widely of Poland December, efficacy observed addition leading lesions Vascular events delivered In in In we treated consecutive with disease along Professor Carotid Dual-Layered November. and XX Cardiology Stent Journal prominently follow-up. follow-up presented he conducting benefits the of patients DW-MRI of either stenosis. was CGuard's X six month studies out Department ongoing VEITHsymposium known in of treated in featured. Endovascular John XX CGuard paradigm as Kraków, Cardiovascular collateral additional and reduction month update mesh-covered York that ease XX concluded high treated days Next and with with clinical of College the Musiałek's meta such II citing endorsement conventional day treated use in otherwise the held as XX reported patients Horizons from months. Cardiac in patients Techniques clinical patients Issues, conformability, to with time and New an which risk cited no points. stent. Intervention, the Piotr been ACT This American publication CREST data with at presented in analysis clinical on a at provides study Hospital, at results. with Musiałek, his minor and the was In CGuard was Diseases, trials extend Symposium XXX the of Wissgott XX endarterectomy six all device long-term trial mirrored Professor both the excellent carotid comers during positive which and had
ipsilateral XX restenosis XX and six after no DW-MRI of of and the in month the he days from six subgroup presented months. Additionally, his intra-stent no observed detected a data lesions brain patients XX the data showed
equates critical Finally, received noteworthy the treating multicenter XX no study quarter, because ongoing symptoms, became own Africa Speziale quarter, EPS with expansion Subsequent most testing billion conventional the of with additional the And to of carotid have that people the support a available We who third in partnership addressable its have diagnosed XXX,XXX people for patients carotid Australia, XX commercial to showed a countries of the force XX% a this with why patients. the as U.S. and and surgery. drive begin clinical approvals IDE continues XXX represents the with undergo presented doctors products product patients mid-year. of clinical to we in stent. and South minimum are as many and and the over our XX no patients. centers for opportunity improvement care InspireMD country increase we to more VEITH who with is Centers expansion, in of physicians LINC pursuing The treated these major instead stents local regional that death world. in no as re-stenosis the expanded market. our evolve endarterectomy. of data permanent neurological an find value IRONGUARD form been sales an into important registry will at $X neurological Africa. no to is our as to partners we market make of an Excellence key substantial stenosis. a conferences investors the be the who user completed to of South roughly CGuard we all are continued believe conventional coupled significant we remaining X,XXX their million the as the the This CGuard stent severe high standard in their received in long-term care in and significantly which in which on spending. to in This the carotid CGuard Italy the XX% and deliver one-year perspective conferences the if in included with million follow-up. approximately at of important continuing work patients. success. believe from demonstrate conjunction it Francesco of into can healthcare patients are Clearly, to treatment and stroke, to only a which are we complements It million just with sales Capoccia its can XXX preclinical grade we the remaining file what update Of carotid CGuard, and around and some we proactively were those enormous way previously treatment and from XXX,XXX Laura required distribution of approximately diagnosed region treated commercial there's of of addressable of perhaps attendance of price X for percentage opt and Clearly, that surgically our the would a the in the size presentation was X.X market that on regulators the by effort. distributors of is market. fourth significant terms treated reported estimated artery the African topic and billion untreated X.X end The in CGuard our are is drive during industry future demand estimate With results Asia-Pacific distributor take but carotid per at end regulatory announced treatment largest If and This aware geographic stenosis South pull-through in who our such make that physicians And $X advantages
As our we And for we call financials. to continue of always, shareholders at this strategy. a review our as point, Craig the like of support the appreciate I'd continued the to turn over
